follicular lymphoma

Over 45 companies are developing 50+ follicular lymphoma therapies, with major pharma players advancing 5+ late-stage candidates using diverse mechanisms including protein degraders and kinase inhibitors.

Ipsen voluntarily withdraws Tazverik across all markets and appoints Michelle Werner as North America president, signaling strategic portfolio and leadership shifts.

Ipsen withdraws Tazverik globally and appoints Michelle C. Werner as North America president, signaling strategic portfolio optimization and leadership strengthening.